Ustekinumab Decreases Circulating Th17 Cells in Ulcerative Colitis
-
- Imazu Noriyuki
- Department of Medicine and Clinical Science, Graduate School of Medical Sciences, Kyushu University, Japan
-
- Torisu Takehiro
- Department of Medicine and Clinical Science, Graduate School of Medical Sciences, Kyushu University, Japan
-
- Ihara Yutaro
- Department of Medicine and Clinical Science, Graduate School of Medical Sciences, Kyushu University, Japan
-
- Umeno Junji
- Department of Medicine and Clinical Science, Graduate School of Medical Sciences, Kyushu University, Japan
-
- Kawasaki Keisuke
- Department of Medicine and Clinical Science, Graduate School of Medical Sciences, Kyushu University, Japan
-
- Fujioka Shin
- Department of Endoscopic Diagnostics and Therapeutics, Kyushu University Hospital, Japan
-
- Fuyuno Yuta
- Department of Medicine and Clinical Science, Graduate School of Medical Sciences, Kyushu University, Japan
-
- Matsuno Yuichi
- Department of Medicine and Clinical Science, Graduate School of Medical Sciences, Kyushu University, Japan
-
- Moriyama Tomohiko
- Department of International Medical, Kyushu University Hospital, Japan
-
- Kitazono Takanari
- Department of Medicine and Clinical Science, Graduate School of Medical Sciences, Kyushu University, Japan
Description
<p>Objective T helper (Th) cells play a central role in the pathogenesis of ulcerative colitis (UC). The present study analyzed the changes in circulating T cells by administration of ustekinumab (UST), an interleukin-12/23p40 antibody. </p><p>Methods CD4 T cells were isolated from peripheral blood at 0 and 8 weeks after UST treatment, and we analyzed the proportion of CD4 T cells by flow cytometry. Clinical information and laboratory data were obtained at 0, 8, and 16 weeks. </p><p>Patients We evaluated 13 patients with UC who received UST for the induction of remission between July 2020 and August 2021. </p><p>Results The median partial Mayo score improved from 4 (1-7) to 0 (0-6) (p<0.001) with UST. Among serological parameters, albumin concentrations, C-reactive protein concentrations, the sedimentation rate, and leucine-rich alpha 2 glycoprotein concentrations showed significant improvement with UST. A flow cytometric analysis of circulating CD4 T cells showed that the percentage of Th17 cells was significantly decreased by UST treatment in all patients (1.85% to 0.98%, p<0.0001). Th1 cells were significantly increased by UST treatment (9.52% to 10.4%, p<0.05), but Th2 and regulatory T cells were not significantly different. The high-Th17 subgroup had a significantly better partial Mayo score than the low-Th17 subgroup at 16 weeks after UST treatment (0 vs. 1, p=0.028). </p><p>Conclusion Treatment with UST decreases circulating Th17 cells, suggesting that this change may be related to the anti-inflammatory effect of UC. </p>
Journal
-
- Internal Medicine
-
Internal Medicine 63 (2), 153-158, 2024-01-15
The Japanese Society of Internal Medicine